ONCE Spark Therapeutics, Inc.

55.62
+0.33  (1%)
Previous Close 55.29
Open 55.61
Price To book 5.93
Market Cap 1.73B
Shares 31,128,000
Volume 337,159
Short Ratio 12.66
Av. Daily Volume 267,387

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initial data due July or August 2017.
SPK-8011
Hemophilia A
Phase 1/2 updated data at ASH 2016. Further update released April 6, 2017.
SPK-9001
Hemophilia B
Phase 1/2 dosing commenced 1Q 2015. Initial data released May 9, 2017.
SPK-7001 (SPK-CHM)
Choroideremia
BLA filing completed - May 18, 2017.
Voretigene neparvovec (SPK-RPE65)
Inherited retinal dystrophies

Latest News

  1. ETFs with exposure to Spark Therapeutics, Inc. : May 25, 2017
  2. Spark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
  3. Spark completes FDA application for gene therapy candidate to repair vision loss
  4. Spark Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ONCE-US : May 18, 2017
  5. Spark Therapeutics Completes Rolling Biologics License Application Submission to FDA for Investigational Gene Therapy Voretigene Neparvovec
  6. Edited Transcript of ONCE earnings conference call or presentation 9-May-17 12:30pm GMT
  7. Spark Therapeutics reports 1Q loss
  8. Spark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress
  9. Spark Therapeutics to Participate in Multiple Meetings in May
  10. Spark Therapeutics to Host Conference Call on Tuesday, May 9 at 8:30 a.m. to Discuss Q1 2017 Results
  11. Spark Therapeutics, Inc. – Value Analysis (NASDAQ:ONCE) : April 27, 2017
  12. Spark Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ONCE-US : April 26, 2017
  13. Mystery Clot Reveals a Helpful Mutant Gene in Hunt for a Cure
  14. ETFs with exposure to Spark Therapeutics, Inc. : April 7, 2017
  15. Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at the Hemostasis and Thrombosis Research Society (HTRS) 2017 Scientific Symposium
  16. Spark Therapeutics to Present Updated Hemophilia B Data at the Hemostasis and Thrombosis Research Society (HTRS) 2017 Scientific Symposium
  17. ETFs with exposure to Spark Therapeutics, Inc. : March 27, 2017
  18. Spark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  19. 3 Biotech Stocks to Buy in March